Antiplatelet drugs and the perioperative period: What every urologist needs to know

Indian Journal of Urology

Volumn 25, Issue 3, 2009, Pages 296-301

  Vasudeva, Pawan ^a   Goel, Apul ^a   Sengottayan, Vengetesh K ^a   Sankhwar, Satyanarayan ^a   Dalela, Divakar ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Antiplatelet drugs; Aspirin; Hemorrhage; Perioperative period; Thrombosis; TURP

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; THIENOPYRIDINE DERIVATIVE; THROMBOXANE; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; ARTERY THROMBOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BARE METAL STENT; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FIBRINOLYSIS; HEART INFARCTION; HEMATURIA; HEMOSPERMIA; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; NEUTROPENIA; PERIOPERATIVE PERIOD; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROSTATE BIOPSY; PROSTATECTOMY; RECTUM HEMORRHAGE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; STENT THROMBOSIS; STROKE; SURGICAL RISK; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSURETHRAL RESECTION;

EID: 70349798903     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.56174     Document Type: Review

References (41)

1. Shahar E, Folsom AR, Romm FJ, Bisgard KM, Metcalf PA, Crum L, et al. Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 1996;131:915-922
2. Siva PG, Kekre NS. Should the aspirin (Acetyl salicylic acid) be stopped before trans-urethral surgery. Indian J Urol 2006;22:59-60.
3. Enver MK, Hoh I, Chinegwundoh FI. The management of aspirin in transurethral prostatectomy: current practice in the UK. Ann R Coll Surg Engl 2006;88:280-283
4. Mitchell SM, Sethia KK. Hazards of aspirin withdrawal before transurethral prostatectomy. BJU Int 1999;84:530.
5. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995;332:75-79
6. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494
7. Fitzgerald DJ, Roy L, Catella F, Fitz Gerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989
8. van Kooten F, Ciabattoni G, Patrono C, Dippel DW, Koudstaal PJ. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke 1997;28:1557-1563
9. Shah PK. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion Prog Cardiovasc Dis 2002;44:357-368
10. Badimon L, Vilahur G. Platelets, arterial thrombosis and cerebral ischemia. Cerebrovasc Dis 2007;24:30-39
11. Pratico D, Tillmann C, Zhang ZB, Li H, Fitz Gerald GA. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A 2001;98:3358-3363
12. Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000;96:3823-3826
13. Koyama H, Maeno T, Fukumoto S, Shoji T, Yamane T, Yokoyama H, et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 2003;108:524-529
14. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313
15. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
16. Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:776S-814S.
17. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P; American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:630S-69S.
18. Sobel M, Verhaeghe R; American College of Chest Physicians; American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:815S-43S.
19. Cannon CP. Elderly patients with acute coronary syndromes; higher risk and greater benefit from antiplatelet therapy and/or interventional therapies. Am J Geriatr Cardiol 2003;12:259-262
20. Dornbrook-Lavender KA, Pieper JA, Roth MT. Primary prevention of coronary heart disease in the elderly. Ann Pharmacother 2003;37:1654-1663
21. Billett HH. Antiplatelet agents and arterial thrombosis. Cardiol Clin 2008;26:189-201.
22. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-2383
23. Savi P, Herbert JM. Clopidogrel and ticlopidine: p2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005:31;174-183
24. Weber AA, Braun M, Hohlfeld T, Schwippert B, Tschope D, Schror K. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol 2001;52:333-336
25. Thurston AV, Briant SL. Aspirin and post-prostatectomy haemorrhage. Br J Urol 1993;71:574-576
26. Wierod FS, Frandsen NJ, Jacobsen JD, Hartvigsen A, Olsen PR. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scand J Urol Nephrol 1998;32:120-122
27. Ala-Opas MY, Gronlund SS. Blood loss in long-term aspirin users undergoing transurethral prostatectomy. Scand J Urol Nephrol 1996;30:203-206
28. Nielsen JD, Holm-Nielsen A, Jespersen J, Vinther CC, Settgast IW, Gram J. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy.a prospective, randomized, double- blind, placebo-controlled study. Scand J Urol Nephrol 2000;34:194-198
29. Ehrlich Y, Yossepowitch O, Margel D, Lask D, Livne PM, Baniel J. Early initiation of aspirin after prostate and transurethral bladder surgeries is not associated with increased incidence of postoperative bleeding: a prospective, randomized trial. J Urol 2007;178:524-528
30. Herget EJ, Saliken JC, Donnelly BJ, Gray RR, Wiseman D, Brunet G. Transrectal ultrasound-guided biopsy of the prostate: relation between ASA use and bleeding complications. Can Assoc Radiol J 1999;50:173-176
31. Maan Z, Cutting CW, Patel U, Kerry S, Pietrzak P, Perry MJ, et al. Morbidity of transrectal ultrasonography-guided prostate biopsies in patients after the continued use of low-dose aspirin. BJU Int 2003;91:798-800.
32. Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, et al. Continuing or discontinuing low-dose aspirin before transrectal prostate biopsy: results of a prospective randomized trial. Urology 2007;70:501-505
33. Halliwell OT, Yadegafar G, Lane C, Dewbury KC. Transrectal ultrasound- guided biopsy of the prostate: Aspirin increases the incidence of minor bleeding complications. Clin Radiol 2008;63:557-561
34. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention.cardiovascular risks after its preoperative withdrawal versus bleeding risks with its continuation. review and meta-analysis. J Int Med 2005;257:399-414.
35. Priebe HJ. Triggers of perioperative myocardial ischaemia and infarction. Br J Anaesth 2004;93: 9-20.
36. Howard-Alpe GM, de Bono J, Hudsmith L, Orr WP, Foex P, Sear JW. Coronary artery stents and non-cardiac surgery. Br J Anaesth 2007;98:560-574
37. Beving H, Zhao C, Albage A, Ivert T. Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment . Blood Coagulation Fibrinolysis 1996;7:80-84
38. Sharma AK, Ajani AE, Hamwi SM, Maniar P, Lakhani SV, Waksman R, et al. Major noncardiac surgery following coronary stenting: When is it safe to operate? Catheter Cardiovasc Interv 2004;63:141-145
39. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:299S-339S.
40. Samama CM, Djoudi R, Lecompte T, Nathan N, Schved JF; French Health Products Safety Agency (AFSSAPS) Expert Group. Perioperative platelet transfusion. Recommendations of the French Health Products Safety Agency (AFSSAPS) 2003. Minerva Anestesiol 2006;72:447-452
41. Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy the case for continuing therapy in patients at risk of myocardia infarction. Br J Anaesth 2007;99:316-328